J&J discontinues dengue drug study

(Reuters) -Johnson & Johnson said on Friday it will discontinue a mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.



The decision to discontinue the study was part of a reprioritization of the company's communicable diseases research and development portfolio, J&J (NYSE:JNJ ) said.

In another mid-stage study, six of 10 participants on the drug mosnodenvir showed no detectable dengue virus in their blood after being exposed to the pathogen.

Source: Investing.com